The program is to investigate the use of a nanoparticle CBD formulation (with less than 2% total other cannabinoids) for the treatment and management of anxiety in adults.
NanoCBD is a non-ARTG item manufactured in a US FDA facility and open to compassionate use outside the clinical investigation on an approved named patient basis via the AU Special Access Scheme.
Anxiety is a diverse topic in both severity and potential therapeutic/lifestyle support; regardless of population data shows that anxiety is a growing field, suggesting that current treatment regimens are less effective.
The most prevalent mental illnesses in Australia are Depression, Anxiety and Substance use disorders (ABS 2008).
Cannabidiol (CBD) is a cannabinoid of the Cannabis plant, which has potential therapeutic properties across many neuropsychiatric (anxiety and mood) disorders.
Source: Lee JLC, Bertoglio LJ, Guimaraes FS, et al. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. 2017;174:3242–3256.
Anxiety disorders are chronic, disabling conditions and represent the most prevalent mental illnesses in the world, with high societal costs.
Source: Scherma M, Masia P, Deidda M, et al. New perspectives on the use of cannabis in the treatment of psychiatric disorders. Medicines (Basel). 2018;5:pii: E107. Google Scholar.
Anxiety is identified as having excessive anticipation of future threats and accompanied by excessive fear, which is an emotional response to imminent threats. These feelings can have physical symptoms such as poor sleep, concentration and dizziness issues and occasionally heart palpitations.
Source: American Psychological Association (APA). Diagnostic and Statistical Manual of Mental Disorders (5th Edition). American Psychological Association: Washington, DC, 2013. Crossref, Google Scholar.